MedTrace Logo

Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor

NCT01504906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-12-12

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of Cyclosporine on the blood levels of Ticagrelor.

Conditions

  • Healthy

Interventions

DRUG

cyclosporine

Oral tablets, 600 mg , single dose

DRUG

ticagrelor

Oral tablets, 180 mg, single dose

Sponsors & Collaborators

Principal Investigators

  • Kelli Craven, MD · Overland Park US, Quintiles, Inc.

  • Miriana Kujacic, MD · Molndal, Sweden AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01504906 on ClinicalTrials.gov